James Poe

Mr. James Poe

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
MAMatthew A Abikenari
Matthew A Abikenari
GNGeorge Nageeb
George Nageeb
JHJoseph H. Ha
Joseph H. Ha
MSMatthew Adam Sjoholm
Matthew Adam Sjoholm
JLJustin Liu
Justin Liu
MLMichael Lim
Michael Lim
Glioblastoma (GBM) is a universally fatal cancer for which the standard of care has remained largely unchanged for the last 20 years. Recent work has demonstrated that most therapeutic trials for GBM fail due to complex mechanisms of immunosuppression mediated by both the innate and adaptive immune systems. Various metabolic alterations in the tumor microenvironment help maintain this local and systemic immunosuppression, of which the axis of hypoxia-driven tryptophan degradation has garnered substantial attention over the last decade. This paper synthesizes a much-needed elucidation of the immunometabolic reshaping of glioma, myeloid, endothelial, and lymphoid cell lineages induced by hypoxia. The current paper critically evaluates the role of IDO1/TDO2-mediated breakdown of tryptophan and the consequent accumulation of kynurenine, a metabolite that triggers GCN2- and AHR-mediated CD8+ T-cell exhaustion and supports regulatory T-cell differentiation and expansion. Furthermore, we propose a synthesis of mechanistic evidence that establishes a role for the Trp-GCN2-ATF4-VEGFA axis in hypoxia-induced immunosuppression, supporting that pro-tumoral metabolic dysregulation is directly linked to angiogenesis. In GBM, hypoxia and tryptophan–kynurenine pathway dysregulation operate as an integrated metabolic circuit that drives widespread immunosuppression. These mechanisms can be captured by a metabolic signature shared across nearly every cell type in the GBM microenvironment. Drawing on recent spatial transcriptomic, metabolomic, and pharmacologic studies, we outline how this metabolic axis shapes disease biology and how it can be targeted to restore effective antitumor immunity.

20 March 2026 in Cells
Verified
Journal Article
Open access
PDF file
JPJames Poe
James Poe
CKClaire Chae-Lin Kim
Claire Chae-Lin Kim
CCCampbell Coleman
Campbell Coleman
HNHoang Minh Hieu Nguyen
Hoang Minh Hieu Nguyen
VVVaithish Velazhahan
Vaithish Velazhahan
MLMichael Lim
Michael Lim
Glioblastoma (GBM) persists as one of the greatest challenges in the treatment of human cancer, despite extensive efforts to leverage the therapeutic potential of immunotherapy. While checkpoint blockade and other forms of immunotherapy have revolutionized the treatment of various cancers, their therapeutic efficacy in GBM has been hindered by the profound immunosuppressive environment, spatial heterogeneity, and dynamic immune metabolic challenges associated with the tumor microenvironment. In this review, we will synthesize recent advances and insights to develop a next-generation framework for GBM immunotherapy based on systems biology approaches to understanding the complex interplay between GBM and the immune system, as opposed to single-axis approaches to immune activation and modulation. We will discuss how the functional competence of the interferon system, myeloid antigen presentation status, T-cell clone status, spatial organization of the immune microenvironment, and resource competition between GBM and the immune system dictate therapeutic responsiveness. Furthermore, the current paper elucidates how recent advances in spatial transcriptomics, single-cell analysis, and high-parameter imaging enable us to understand how immune phenotype status varies across GBM regions and treatment status, and how this information can be used to develop predictive and pharmacodynamic biomarkers of therapeutic efficacy and failure. We will then discuss how these advances form the basis for rational combination approaches to GBM immunotherapy, which involve the integration of checkpoint blockade with metabolic reprogramming, myeloid modulation, and interferon system reactivation, and how artificial intelligence-based analytics and adaptive clinical trial design can guide the development of biomarker-based therapeutic selection approaches.

26 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MAMatthew A Abikenari
Matthew A Abikenari
JCJohn Choi
John Choi
IEIman Enayati
Iman Enayati
ATAndrew Tucker
Andrew Tucker
KBKeshav Bhatnagar
Keshav Bhatnagar
DODerick Okwan-Duodu
Derick Okwan-Duodu
Thymic malignancies are rare cancers arising from thymic epithelial cells and are characterized by a highly diverse clinical phenotype, substantial histologic and morphologic heterogeneity, and frequent associations with autoimmune syndromes. Although the clinical, immunological, and cytoarchitectural changes associated with thymomas have been increasingly elucidated in the contemporary literature, very few studies have interrogated the direct role of tumor staging and histological grading in shaping autoimmunity burden and infection risk. In this narrative review, we synthesize contemporary clinical, immunological, and morphologic evidence linking thymic architecture and selection defects to the spectrum of paraneoplastic autoimmunity (MG, pure red cell aplasia, Good’s syndrome) and to infectious vulnerability. We further appraise emerging therapeutic strategies, including immune checkpoint inhibition and adoptive cellular approaches, through a patient-stratified lens, emphasizing efficacy signals, immune-related adverse events, and practical considerations for selection and monitoring. We conclude by highlighting priorities for future investigation, including refining autoantibody signatures; mapping thymic microenvironments that drive tolerance failure, and prospectively evaluating stratified immunotherapeutic regimens that balance benefit with immune-mediated risk.

1 September 2025 in Stereotactic and Functional Neurosurgery
Verified
Journal Article
Closed access
ASAdithya Sivaraju
Adithya Sivaraju
JPJames Poe
James Poe
HBHal Blumenfeld
Hal Blumenfeld
ACArthur Cukiert
Arthur Cukiert
Introduction: Deep brain stimulation (DBS) of the centromedian (CM) thalamic nucleus is a potential therapy for Lennox-Gastaut syndrome (LGS), a severe and drug-resistant epileptic encephalopathy. While long-term seizure outcomes with CM-DBS have been described, its acute electrophysiological effects and predictive value remain uncertain. We examined whether short-term changes in interictal epileptiform discharges (IEDs) following CM-DBS relate to seizure outcomes at 1 year. Methods: Ten patients with LGS underwent CM-DBS implantation. About 1 month post-surgery, each patient had a 1-h scalp EEG. After a 10-min baseline, stimulation began at 1 V for 5 min, increasing in 1 V increments to 5 V or until paresthesias occurred. IEDs were detected automatically (Persyst v14c) and verified by an expert reviewer. Patients were followed for 1 year, with clinical response defined as ≥50% seizure reduction, i.e., responder. Correlations between acute IED change and seizure outcomes were assessed using Spearman’s rank correlation. Results: Nine of 10 patients showed reduced IED burden during acute stimulation (31%–100%). At 1 year, 8 were responders and 2 nonresponders. Overall, acute IED reduction did not correlate with seizure outcome (Spearman’s ρ = 0.3, p = 0.35). A ≥50% reduction in IED burden was seen in 7 of 7 responders versus 1 of 3 nonresponders, suggesting a nonsignificant trend toward predictive value (p = 0.06). Conclusion: Acute CM-DBS reduced IED burden in most patients with LGS but did not significantly predict long-term seizure outcomes. A trend toward greater IED reduction in responders suggests possible biomarker potential, though findings are preliminary and hypothesis-generating. Limitations include small sample size, high responder rate, and short EEG duration. Larger studies with extended monitoring are needed to clarify the clinical utility of acute EEG changes as predictors of CM-DBS efficacy.

23 October 2026 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
GTGavin Touponse
Gavin Touponse
SBSerena Bidwell
Serena Bidwell
ASAmei Shank
Amei Shank
JTJesse Tai
Jesse Tai
JPJames Poe
James Poe
JCJeff Choi
Jeff Choi
BACKGROUND: Understanding the publication rates and citation patterns of conference abstracts is critical for program committees and investigators alike. However, the downstream scholarly outcome of conference abstracts remains poorly characterized. We hypothesized that across contemporary US trauma-related scientific meetings, a substantial proportion of conference abstracts would not progress to peer-reviewed publications, and that publication rates and citation patterns would vary by presentation format and conference. METHODS: We conducted a cross-sectional study of abstracts presented at four major US trauma surgery conferences from 2017 to 2019. We identified peer-reviewed manuscripts associated with conference abstracts via Google Scholar and PubMed. We collected presentation format, publishing journal, 2024 journal impact factor, and citation count. A cohort of directly submitted peer-reviewed manuscripts was also analyzed. Mixed-effects Poisson regression models assessed the association between presentation and citation counts, adjusting for publication timing. RESULTS: Of 1,157 abstracts, 762 (66%) were published as peer-reviewed manuscripts. Most manuscripts were published in the Journal of Trauma and Acute Care Surgery ( JTACS ) (55%), with 5 in journals with a higher-impact factor than JTACS . On regression analysis, abstracts presented as oral presentations, and published in journals with an impact factor higher than JTACS , were associated with a greater number of citations. When comparing manuscripts presented as abstracts to directly submitted peer-reviewed manuscripts, abstract presentation was associated with 22% more citations (incidence rate ratio: 1.22; 95% CI [1.16–1.29]; p <0.001). CONCLUSIONS: This cross-sectional study of four trauma societies found that approximately a third of presented abstracts did not progress to peer-reviewed publication, with publication rates varying by conference and presentation format. Exploratory analyses found that among those published in JTACS , published manuscripts originating from presented abstracts demonstrated a modestly higher citation count compared with directly submitted manuscripts. Our findings highlight an opportunity to better understand how conference time and investigator effort translate into downstream scholarly output. LEVEL OF EVIDENCE: Prognostic/Epidemiological; Level IV.